相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma
Sean McBride et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?
Erminia Romano et al.
CANCERS (2021)
Patterns of Response to Immune Checkpoint Inhibitors in Association with Genomic and Clinical Features in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC)
Panagiota Economopoulou et al.
CANCERS (2021)
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Nancy Y Lee et al.
LANCET ONCOLOGY (2021)
Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
J. Bourhis et al.
ANNALS OF ONCOLOGY (2021)
Platinum Derivatives Effects on Anticancer Immune Response
Cedric Rebe et al.
BIOMOLECULES (2020)
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study
Steven F. Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness et al.
LANCET (2019)
Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy
Y. -P. Chen et al.
ANNALS OF ONCOLOGY (2019)
Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy
Ariel E. Marciscano et al.
CLINICAL CANCER RESEARCH (2018)
Combining Immunotherapy and Radiotherapy for Cancer Treatment Current Challenges and Future Directions
Yifan Wang et al.
FRONTIERS IN PHARMACOLOGY (2018)
Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation
Zachary S. Buchwald et al.
FRONTIERS IN ONCOLOGY (2018)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The promise of immunotherapy in head and neck squamous cell carcinoma
P. Economopoulou et al.
ANNALS OF ONCOLOGY (2016)
Definitive chemoradiation alters the immunologic landscape and immune checkpoints in head and neck cancer
Vishwajith Sridharan et al.
BRITISH JOURNAL OF CANCER (2016)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Radiotherapy and Immunogenic Cell Death
Encouse B. Golden et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
Role of Local Radiation Therapy in Cancer Immunotherapy
Sandra Demaria et al.
JAMA ONCOLOGY (2015)
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Simon J. Dovedi et al.
CANCER RESEARCH (2014)
Systemic effects of local radiotherapy
Silvia C. Formenti et al.
LANCET ONCOLOGY (2009)
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
Eric A. Reits et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
分享论文
